Our long-term objective is to determine the function of intestinal cytochrome P450 (P450) enzymes in drug metabolism and toxicity. The focus of this proposal is on the characterization of a novel transgenic mouse model for studying the in vivo function of intestinal P450 enzymes in drug/xenobiotic clearance. In preliminary studies, we have generated an intestinal epithelium (IE)-specific NADPH-cytochrome P450 reductase (Cpr) gene knockout mouse model (designated IE-Cpr-null). The gene product of Cpr is the obligatory electron donor to all microsomal P450s. Thus, using the IE-Cpr-null mouse model, we can study the combined roles of IE microsomal P450 enzymes in intestinal xenobiotic metabolism and toxicity. We will use this mouse model to test the central hypothesis that IE P450-mediated drug metabolism can substantially lower the oral bioavailability of numerous drugs/xenobiotics.
In Aim 1, we will further characterize the newly generated IE-Cpr-null mouse, in order to identify its full utility.
In Aim 2, we will directly determine the role of IE CPR/P450s in the first-pass clearance of oral drugs using the IE-Cpr-null mouse model.
In Aim 3, we will test the hypothesis that small intestinal P450-mediated first-pass clearance of ingested dietary or xenobiotic chemicals influences the ability of these chemicals to regulate gene expression in the small intestine and extra-gut organs. Through the proposed studies, we hope to establish the utility of the novel IE-Cpr-null mouse model for identifying those oral drugs/xenobiotics, for which systemic bioavailability (which affects drug efficacy or, alternatively, extent of adverse drug reactions) is substantially influenced by SI P450-mediated first-pass metabolism.
The mutant mouse named IE-Cpr-null will be a powerful tool for determination of the role of intestinal P450 enzymes in limiting the systemic levels of numerous drugs and other foreign chemicals and dietary ingredients. Such knowledge is currently difficult to obtain, and yet is critical for optimizing the effectiveness and safety of numerous clinically important drugs.
|Xie, Fang; Ding, Xinxin; Zhang, Qing-Yu (2016) An update on the role of intestinal cytochrome P450 enzymes in drug disposition. Acta Pharm Sin B 6:374-383|
|Zhu, Yi; Xie, Fang; Ding, Liang et al. (2015) Intestinal epithelium-specific knockout of the cytochrome P450 reductase gene exacerbates dextran sulfate sodium-induced colitis. J Pharmacol Exp Ther 354:10-7|
|Levinson, Kara J; Giffen, Samantha R; Pauly, Michael H et al. (2015) Plant-based production of two chimeric monoclonal IgG antibodies directed against immunodominant epitopes of Vibrio cholerae lipopolysaccharide. J Immunol Methods 422:111-7|
|Turesky, Robert J; Konorev, Dmitri; Fan, Xiaoyu et al. (2015) Effect of Cytochrome P450 Reductase Deficiency on 2-Amino-9H-pyrido[2,3-b]indole Metabolism and DNA Adduct Formation in Liver and Extrahepatic Tissues of Mice. Chem Res Toxicol 28:2400-10|
|Levinson, Kara J; De Jesus, Magdia; Mantis, Nicholas J (2015) Rapid effects of a protective O-polysaccharide-specific monoclonal IgA on Vibrio cholerae agglutination, motility, and surface morphology. Infect Immun 83:1674-83|
|Megaraj, Vandana; Ding, Xinxin; Fang, Cheng et al. (2014) Role of hepatic and intestinal p450 enzymes in the metabolic activation of the colon carcinogen azoxymethane in mice. Chem Res Toxicol 27:656-62|
|De Jesus, Magdia; Ostroff, Gary R; Levitz, Stuart M et al. (2014) A population of Langerin-positive dendritic cells in murine Peyer's patches involved in sampling Î²-glucan microparticles. PLoS One 9:e91002|
|Ahlawat, Sarita; Xie, Fang; Zhu, Yi et al. (2014) Mice deficient in intestinal epithelium cytochrome P450 reductase are prone to acute toxin-induced mucosal damage. Sci Rep 4:5551|
|Ahlawat, Sarita; De Jesus, Magdia; Khare, Kedar et al. (2014) Three-dimensional reconstruction of murine Peyer's patches from immunostained cryosections. Microsc Microanal 20:198-205|
|Zhu, Yi; Ding, Xinxin; Fang, Cheng et al. (2014) Regulation of intestinal cytochrome P450 expression by hepatic cytochrome P450: possible involvement of fibroblast growth factor 15 and impact on systemic drug exposure. Mol Pharmacol 85:139-47|
Showing the most recent 10 out of 20 publications